CD38 expression

Can check CD38 expression on the MZL and consider Dara/len based therapy which might work for both (@drjoannarhodes1)

66,♂️, no co-morbidities, living w/ CLL for 12 yrs now 4 yrs w/w 5 yrs of ibrutinib 3 yrs Ven+R Now del17p+ IGHv status not known CD38 expression⤴️ No pirtobrutinib available Acalabrutinib generic but don't know if C481 mutated🤷‍♂️ Options ? @NitinJainMD @BijoyTelivala (@nihardesai7)

Daratumumab mechanisms of resistance in myeloma: 1) Clone selection of CD38dim MM cells 2) CD38 reduction via CD38 endocytosis, trogocytosis by granulocytes & monocytes, & via release of CD38-expressing microvescicles that contribute to ADO production #mmsm #USMIRC #MedTwitter (@Abdallah81MD)

#ASH22 #mmsm - oral - Modakafusp ✅Early results. See AEs, pneumonia G3 in 1 out of 4 patients enrolled. activity independent of peripheral blood immune cell CD38 expression ✅1.5 mg/kg Q4W for future studies. (@HadidiSamer)

Fortunately Daratumumab works for CD20+ myeloma due to ubiquitous expression of CD38 by all subtypes of myeloma cells (@ChaulagainMD)

#Myeloma Paper of the Day: Study of the efficacy and safety of #Darzalex + #ATRA in relapsed/refractory #myeloma finds ATRA transiently enhances CD38 expression but does not resensitize to #Darzalex, with response rate of only 4.5%: https://t.co/ObUXPrYHLf. (@Myeloma_Doc)

Efficacy and Safety of Daratumumab w ATRA in RRMM.The combination has limited activity in daratumumab-refractory MM pts. The limited efficacy may be partially explained by the transient increase in CD38 expression upon ATRA treatment https://t.co/d0DbW7gIeI #mmsm #MedTwitter (@Abdallah81MD)

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Patients with t(11;14) have: - Lower CD38 - Lower CD138 - Higher PAX5 & CD79A - Higher BCL2/BCL2L1 ratio #mmsm https://t.co/dBc3Cco9ca (@Rfonsi1)

Loss of CD38 expression in myelomatous pleural effusion in a patient with myeloma treated with daratumumab: Report of a case https://t.co/HX3npgY6ab #mmsm (@Rfonsi1)

#Myeloma Paper of the Day: Pre-clinical data show that the BCMA-specific ADC MEDI2228 and #Darzalex induce synergistic #myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression: https://t.co/jAuK6Ms0HM. (@Myeloma_Doc)

A lesson don’t assume the car T cells are without toxicity the expression of CD38 in parts of the central nervous system has led to a range of long term CNS effects. #mmsm #iwMyeloma21 (@DrGarethMorgan1)